Enrique Poradosu's Insider Trades & SAST Disclosures
Enrique Poradosu's most recent trade in Nuvectis Pharma Inc was a trade of 150,000 Common Stock done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Enrique Poradosu.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 150,000 | 1,656,319 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 4.99 per share. | 19 Nov 2024 | 2,000 | 1,506,319 | - | 5.0 | 9,980 | Common Stock |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 6.29 per share. | 10 May 2024 | 500 | 1,504,319 | - | 6.3 | 3,145 | Common Stock |
| Nuvectis Pharma Inc | Poradosu Enrique | Chief Science & Business Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 130,000 | 1,503,819 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 11.55 per share. | 27 Mar 2023 | 500 | 1,373,819 | - | 11.6 | 5,775 | Common Stock |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 115,000 | 1,373,319 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 14.76 per share. | 12 May 2022 | 370 | 1,258,019 | - | 14.8 | 5,461 | Common Stock |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 16.04 per share. | 12 May 2022 | 300 | 1,258,319 | - | 16.0 | 4,812 | Common Stock |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 60,000 | 1,257,649 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 3.35 per share. | 04 Feb 2022 | 3,800 | 1,196,849 | - | 3.4 | 12,730 | Common Stock, par value $0.00001 |
| Nuvectis Pharma Inc | Enrique Poradosu | Chief Science & Business Off | Purchase of securities on an exchange or from another person at price $ 3.88 per share. | 04 Feb 2022 | 800 | 1,197,649 | - | 3.9 | 3,104 | Common Stock, par value $0.00001 |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges